Sunday, Oct 25, 2026
Focus on the big picture

Lilly drug slows Alzheimer's progression by 35% in trial

Reuters, 04 May 2023
An experimental Alzheimer's drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for another treatment for the brain disorder that slowly destroys memory.

#Alzheimers #donanemab #EliLilly #News #Reuters #newsfeed

Subscribe: http://smarturl.it/reuterssubscribe

Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.

Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Related Articles